Real-World Application of Subcutaneous Efgartigimod in Chronic Inflammatory Demyelinating Polyradiculoneuropathy - PubMed
3 hours ago
- #chronic inflammatory demyelinating polyradiculoneuropathy
- #efgartigimod
- #Fc receptor inhibitors
- Subcutaneous efgartigimod was evaluated in four CIDP patients with varied responses.
- One typical CIDP patient showed marked improvement, while two had limited benefits and discontinued treatment.
- A motor CIDP patient experienced sustained improvement, suggesting motor-dominant symptoms may predict better response.
- No serious adverse events were reported, with only one case of mild post-injection fatigue.
- The study highlights the need for larger studies to identify predictors of efgartigimod responsiveness in CIDP.